CDKN2A and melanoma: In BRAFV600E‐mutant melanoma, increased MEK/ERK activity is accompanied by mutations or inactivation of cell‐cycle regulators like Cyclin‐dependent Kinase inhibitor 2A (CDKN2A) and Tumour Protein 53 (TP53).107